Eptifab (100 ml) Infusion
Generic : Eptifibatide
₹ 209.50 75mg/100ml 100ml
Intravenous- Unstable angina(acute coronary syndrome)- Adult: 180 mcg/kg via IV injection followed by 2 mcg/kg/minute by IV infusion for up to 72 hours. If percutaneous coronary intervention is performed during therapy, infusion should be continued for 18-24 hours after procedure, up to a max total duration of 96 hours of therapy.
Easy bruising or bleeding, pink or red-colored urine, black stool, coffee-ground vomit, one-sided weakness, vision problems, confusion, slurred speech.
Heart: Low blood pressure.
Blood: Reduced platelets, cerebral, GI, and lung bleeding, acute profound thrombocytopenia, fatal bleeding events.
Local: Overall incidence of major bleeding, major bleeding.
It will be administered as an injection at a hospital.
Contraindicated in patients with increased risk of bleeding disorders, brain disorders, history of stroke, uncontrolled hypertension, severe injury, severe kidney impairment, recent major surgery, breastfeeding.
Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic (drugs are used in medicine to dissolve blood clots) therapy is required.
Caution should be exercised in patients with liver impairment, platelet counts <100,000 mm3; bleeding in the eye, drugs affecting blood, pregnancy.
Check aPTT [activated partial thromboplastin time or ACT(activated clotting time) prior to sheath removal during angioplasty.
It may lead to severe kidney impairment, inflammation of blood vessels, bleeding in the eye, acute pericardial inflammation ( inflammation of the covering of the heart)or aortic dissection (splitting of the layers of the aorta leading to formation of outpouchings).
Monitor complete blood counts, serum creatinine levels regularly.
Storage: Store at 25 °C. Store it in airtight container and keep away from children.